-
New approved MG treatment for gMG – Vyvgart Hytrulo
The FDA has approved Argenx’s subcutaneous injection (given in the fatty tissue just under the skin) formulation of efgartigimod, called Vyvgart Hytrulo, to treat adults with generalized myasthenia gravis, https://myastheniagravisnews.com/news/fda-approves-subcutaneous-efgartigimod-vyvgart-hytrulo-gmg/.
Efgartigimod alfa is the active agent in Vyvgart and a recombinant human hyaluronidase PH20 enzyme. That enzyme is crucial in the under-the-skin injection delivery, which takes less than two minutes to be administered.
In comparison, the into-the-vein or intravenous therapy takes about one hour.
This is very exciting! Is anyone eager to discuss this treatment with their doctor to see if you are a candidate?
Log in to reply.